Centro Hospitalar Universitario Do Porto E.P.E.
- Address
- Largo Professor Abel Salazar, 4050-011 Porto, Portugal
Cardiovascular Diseases
Research at the site focuses on atherosclerotic cardiovascular disease and the impact of elevated lipoprotein (a) on heart health, aiming to evaluate new therapies that may lower cardiovascular risk.
- Atherosclerotic cardiovascular disease (ASCVD)
- Elevated lipoprotein (a)
- Coronary heart disease outcomes
The investigations are part of the broader clinical program at Centro Hospitalar Universitario Do Porto E.P.E., integrating multidisciplinary expertise.
Eye Diseases
Trials target visual impairment caused by retinal vein occlusion, testing whether higher doses of anti‑VEGF agents improve best‑corrected visual acuity and reduce macular swelling.
- Macular edema secondary to retinal vein occlusion
- Aflibercept dosing regimens
- Visual acuity outcomes
Patients receive care within the hospital’s ophthalmology collaborations, ensuring comprehensive monitoring.
Immune System Diseases
The department evaluates innovative treatments for autoimmune conditions such as systemic lupus erythematosus and hidradenitis suppurativa, seeking to improve disease control and quality of life.
- Systemic lupus erythematosus (SLE)
- Hidradenitis suppurativa
- Autoimmune disease activity
- Upadacitinib therapy
These studies benefit from the hospital’s strong immunology expertise and patient‑centered approach.
Neoplasms
Oncologic research includes advanced lung cancer subtypes, where agents targeting c‑Met overexpression are compared with standard chemotherapy to extend survival.
- c‑Met high overexpressing non‑small cell lung cancer
- Extensive‑stage small‑cell lung cancer
- Combination chemotherapy
- Targeted antibody‑drug conjugates
Centro Hospitalar Universitario Do Porto’s oncology service provides the clinical infrastructure for these investigations.
Nervous System Diseases
Clinical studies address seizure disorders, assessing novel oral compounds for reduction of primary generalized tonic‑clonic seizures frequency.
- Primary generalized tonic‑clonic seizures
- XEN1101 efficacy
- Seizure frequency reduction
- Placebo‑controlled design
Neurology specialists collaborate with the oncology unit to ensure rigorous safety monitoring.
Nutritional and Metabolic Diseases
Trials explore weight management in pediatric obesity, evaluating the effect of weekly semaglutide injections combined with lifestyle counseling.
- Childhood obesity
- Semaglutide weekly dosing
- Reduced‑calorie diet
- Physical activity promotion
The multidisciplinary team at the hospital integrates nutritionists and endocrinologists for comprehensive care.
Skin and Connective Tissue Diseases
Multiple studies investigate severe eczema and alopecia, testing the efficacy of upadacitinib and rocatinlimab to achieve high skin clearance and hair regrowth.
- Moderate to severe atopic dermatitis
- Severe alopecia areata
- Upadacitinib dose‑flexibility
- Rocatinlimab efficacy
Dermatology experts at the site conduct regular assessments to track therapeutic outcomes.
Immune system processes
Research delves into underlying immune mechanisms, focusing on pathways modulated by Janus kinase inhibition to treat inflammatory skin and systemic diseases.
- Janus kinase (JAK) pathway
- Cytokine signaling modulation
- Inflammatory response assessment
- Biomarker analysis
These mechanistic studies complement the interventional trials conducted at Centro Hospitalar Universitario Do Porto.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 15 therapeutic areas and 15 of 100 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 83 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG2active
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG7trials
lock +10 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centro Hospitalar Universitario Do Porto E.P.E.
lock Showing 1 of 49 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 100 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Upadacitinib | 5 | Unknown | 2019-01-09 | 2024-06-17 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.